Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates

@article{Smith2018AttenuationAE,
  title={Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates},
  author={D. Smith and S. Johnston and Ashley E Piper and Miriam A. Botto and G. Donnelly and J. Shamblin and C. Albari{\~n}o and L. Hensley and C. Schmaljohn and S. Nichol and B. Bird},
  journal={PLoS Neglected Tropical Diseases},
  year={2018},
  volume={12}
}
  • D. Smith, S. Johnston, +8 authors B. Bird
  • Published 2018
  • Biology, Medicine
  • PLoS Neglected Tropical Diseases
  • Rift Valley fever virus (RVFV) is an important mosquito-borne veterinary and human pathogen that has caused large outbreaks of severe disease throughout Africa and the Arabian Peninsula. Currently, no licensed vaccine or therapeutics exists to treat this potentially deadly disease. The explosive nature of RVFV outbreaks and the severe consequences of its accidental or intentional introduction into RVFV-free areas provide the impetus for the development of novel vaccine candidates for use in… CONTINUE READING
    9 Citations
    Candidate vaccines for human Rift Valley fever
    • T. Ikegami
    • Biology, Medicine
    • Expert opinion on biological therapy
    • 2019
    • 2
    Rift Valley Fever: Important Considerations for Risk Mitigation and Future Outbreaks
    • 1
    • PDF
    Rift Valley Fever – epidemiological update and risk of introduction into Europe
    • 2
    • PDF
    Reverse genetics approaches for the development of bunyavirus vaccines.

    References

    SHOWING 1-10 OF 67 REFERENCES
    The pathogenesis of Rift Valley fever virus in the mouse model.
    • 90